Wolf A, Vahrson H, Hoss M
J Cancer Res Clin Oncol. 1980;97(2):153-9. doi: 10.1007/BF00409901.
Determinations of plasma ribonuclease were recommended in 1977 by Sheid et al. for laboratory diagnosis of ovarian carcinoma. We investigated the turnover of transfer ribonucleic acid (tRNA) as the substrate of the enzyme in healthy female inbred rats under the multistep-massive dose therapy of ovarian carcinoma usual at the Department of Gynecology, University of Giessen. Whereas mitopodozide, percutaneous irradiation of the abdomen and teniposide did not have any detectable influence on the enzyme activity, the enzyme was strongly suppressed by the other therapy steps: minima of tRNA turnover were observed on the 2nd day with adriamycine, on the 4th day with methotrexate and methotrexate/folinic acid, on the 6th day with cyclophosphamide and fractionated percutaneous irradiation with cyclophosphamide medication in the intervening periods. According to the results, a plasma ribonuclease determination to check the result of therapy should only be performed at an interval of 2 weeks after each therapy step.
1977年,谢德等人建议测定血浆核糖核酸酶用于卵巢癌的实验室诊断。我们在吉森大学妇科常用的卵巢癌多步骤大剂量治疗方案下,研究了健康雌性近交大鼠体内作为该酶底物的转移核糖核酸(tRNA)的周转情况。丝裂蒽醌、腹部经皮照射和替尼泊苷对酶活性没有任何可检测到的影响,而其他治疗步骤则强烈抑制了该酶:使用阿霉素时在第2天观察到tRNA周转的最小值,使用甲氨蝶呤和甲氨蝶呤/亚叶酸时在第4天,使用环磷酰胺以及在中间阶段使用环磷酰胺药物进行分次经皮照射时在第6天。根据结果,仅应在每个治疗步骤后间隔2周进行血浆核糖核酸酶测定以检查治疗效果。